Falls Church, VANCT06675448Now EnrollingIRB Ready

Mitral Regurgitation Clinical Trial in Falls Church, VA

Access cutting-edge mitral regurgitation treatment through this clinical trial at a research site in Falls Church. Study-provided care at no cost to qualified participants.

Sponsored by Inova Health Care Services

Quick Self-Assessment

See if you qualify for this Falls Church location

Preparing your pre-screening questions…

Expert Care in Falls Church

Access mitral regurgitation specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related mitral regurgitation treatment provided free

Apply for This Falls Church Location

Check if you qualify for this mitral regurgitation clinical trial in Falls Church, VA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Falls Church

    Convenient for VA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Falls Church site if eligible
  4. 4Begin participation

About This Mitral Regurgitation Study in Falls Church

The overarching goal of this research proposal is to study the feasibility and clinical impact of implementing an Inova system-wide heart failure treatment algorithm for patients with symptomatic heart failure due to reduced left ventricular ejection fraction (HFreF) and secondary MR Aim is to check the effectiveness of the IHFTA in identifying patients who are most likely to benefit from percutaneous transcatheter Mitraclip repair in real world

Sponsor: Inova Health Care Services

Who Can Participate

Inclusion Criteria

Symptomatic MR (≥2+) due to cardiomyopathy of either ischemic or nonischemic etiology
Subject has been adequately treated per applicable standards, including for coronary artery disease, LV dysfunction, MR, and HF.
NYHA functional class II, III, or ambulatory IV
Local heart team has determined that MV surgery will not be offered as a treatment option even if the subject is randomized to the Control group.
LVESD ≤70 mm
The primary regurgitant jet , in the opinion of the MitraClip implanting investigator, can be successfully treated by the MitraClip (if a secondary jet exists, it must be considered clinically insignificant).
Transseptal catheterization and femoral vein access is feasible per the MitraClip implanting investigator.
Age 18 y or older
Subject or guardian agrees to all provisions of the protocol
NT-proBNP≥ 1500ng/ml or BNP≥ 300ng/ml

Exclusion Criteria

Untreated clinically significant coronary artery disease requiring revascularization
CABG, PCI, or TAVR within the prior 30 d
Aortic or tricuspid valve disease requiring surgery or transcatheter intervention
COPD requiring continuous home oxygen therapy or chronic outpatient oral steroid use
Cerebrovascular accident within prior 30 d
Severe symptomatic carotid stenosis (N70% by ultrasound)
Carotid surgery or stenting within prior 30 d
ACC/AHA stage D HF
Presence of any of the following:
Estimated PASP N70 mm Hg assessed by site based on echocardiography or right heart catheterization, unless active vasodilator therapy in the catheterization laboratory is able to reduce the PVR to b3 Wood units or between 3 and 4.5 Wood units with v wave less than twice the mean of the PCWP
Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing HF other than dilated cardiomyopathy of either ischemic or nonischemic etiology
Infiltrative cardiomyopathies (eg, amyloidosis, hemochromatosis, sarcoidosis)
Hemodynamic instability requiring inotropic support or mechanical heart assistance
Physical evidence of right-sided congestive HF with echocardiographic evidence of moderate or severe right ventricular dysfunction
Implant of CRT or CRT-D within the last 30 d
Mitral valve orifice area \<4.0 cm2 by site-assessed TTE
Leaflet anatomy which may preclude MitraClip implantation, proper MitraClip positioning on the leaflets, or sufficient reduction in MR by the MitraClip
Hemodynamic instability defined as persistent systolic pressure \<90 mm Hg with or without afterload reduction, cardiogenic shock, or the need for inotropic support or intra-aortic balloon pump or other hemodynamic support device
Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 m
Life expectancy \<12 m due to noncardiac conditions
Investigators opinion a condition that could limit the subject's participation
Status 1 heart transplant or prior orthotopic heart transplantation
Prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve, or any prior transcatheter mitral valve procedure
Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
Active endocarditis or active rheumatic heart disease or leaflets degenerated from rheumatic disease (ie, noncompliant, perforated)
Active infections requiring current antibiotic therapy
TEE is contraindicated or high risk
Known hypersensitivity or contraindication to procedural medications which cannot be adequately managed medically
Pregnant or planning pregnancy within next 12m
Currently participating in an investigational drug or another device study that has not reached its primary end point
Subject belongs to a vulnerable population or has any disorder that compromises his/her ability to give written informed consent and/or to comply with study procedures.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Falls Church?

Yes, this clinical trial (NCT06675448) has an active research site in Falls Church, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Mitral Regurgitation Treatment Options in Falls Church, VA

If you're searching for mitral regurgitation treatment options in Falls Church, VA, this clinical trial (NCT06675448) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Falls Church research site is actively enrolling participants for this clinical trial. You'll receive care from experienced mitral regurgitation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all mitral regurgitation clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Falls Church, VA

See all heart attack clinical trials recruiting in Falls Church — not just this study.

Browse Heart Attack Trials in Falls Church →

Browse More Trials by Condition

Heart Attack TrialsValvular Heart Disease TrialsRheumatoid Arthritis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Falls Church?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Falls Church, VA